Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals (NASDAQ: PHIO) announced definitive agreements to exercise outstanding warrants to purchase an aggregate of 5,663,182 shares of common stock at exercise prices between $2.00 and $5.45, producing expected gross proceeds of approximately $13.4 million before placement agent fees and offering expenses.
The offering closes in two tranches (first close on or about Nov 4, 2025, second close by Nov 18, 2025). Exercising holders will pay an additional $0.125 per new unregistered warrant ($1,415,795.50 aggregate) and receive new unregistered warrants to purchase up to 11,326,364 shares at a $2.05 exercise price, immediately exercisable with a 24‑month term following the resale registration effective date.
Phio intends to use net proceeds for working capital and to accelerate development activities for PH-762 in cutaneous carcinomas after recent positive safety and pathology results.
Phio Pharmaceuticals (NASDAQ: PHIO) reported pathologic results from the fifth and final dose cohort of its Phase 1b INTASYL PH-762 trial in cutaneous carcinomas on November 3, 2025. In the three patients completing the cohort, one had 100% tumor clearance, one had >90% clearance, and one had >50% clearance, with assessments at approximately 5 weeks after initial injection. To date, 18 patients have completed treatment across five cohorts, including 6 complete responses among 16 cSCC patients. The Safety Monitoring Committee reviewed safety at the maximum dose and found no dose-limiting toxicities; overall the trial reports no clinically relevant treatment-emergent adverse effects and dose escalation reached ~20-fold versus cohort 1. Trial identifier: NCT# 06014086.
Phio Pharmaceuticals (NASDAQ: PHIO) announced the appointment of David H. Deming as Lead Independent Director effective October 31, 2025.
Mr. Deming brings over 30 years of investment banking and asset management experience, including more than 27 years at JP Morgan and 12 years leading its Health Group. He joined Phio's board in February 2025 and currently serves on the board's Nominating Committee. The company said his background will support Phio's advancement of its INTASYL gene silencing technology in oncology.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Renmark Financial Communications Live Virtual Non-Deal Roadshow on October 28, 2025 at 12:00 PM EST.
CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing Phase 1b dose-escalation trial of lead compound PH-762 for treatment of skin cancers. The company recently reported positive interim safety and efficacy results from that trial. A live Q&A will follow the presentation and a replay will be available on Renmark's website.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The presentation is scheduled for September 30, 2025, at 12:00 PM EST.
CEO and Chairman Robert Bitterman will discuss the company's proprietary INTASYL gene silencing technology and provide updates on their ongoing clinical trial of PH-762 for skin cancer treatment. The company recently reported positive interim safety and efficacy results from the Phase 1b dose escalation clinical trial.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biopharmaceutical company, will present at the Life Sciences Future Conference on September 26, 2025. CEO Robert Bitterman will provide updates on their ongoing Phase 1b clinical trial for skin cancer using their proprietary INTASYL® siRNA technology.
The presentation will focus on the company's PH-762 development program and discuss strategy and next steps following the treatment phase completion. Management will be available for one-on-one meetings during the conference on September 25-26 at the Sheraton Valley Forge Hotel in King of Prussia, PA.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Robert Bitterman will provide updates on the company's ongoing Phase 1b clinical trial for skin cancer using their INTASYL® siRNA technology.
The presentation is scheduled for September 10, 2025, at 1:30-2 PM EST at the Lotte New York Plaza Hotel. Management will be available for one-on-one meetings throughout the conference, which investors can schedule through H.C. Wainwright representatives.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2025 financial results and provided updates on its Phase 1b clinical trial for PH-762. The trial, evaluating intratumoral PH-762 in various skin cancers, has treated 15 patients across four cohorts with promising results. Among 13 cSCC patients, 5 achieved complete response, 1 near-complete response, and 1 partial response.
The company's cash position strengthened to $10.8 million as of June 30, 2025, up from $5.4 million in December 2024. Q2 2025 resulted in a net loss of $2.2 million, compared to $1.8 million in Q2 2024. In July 2025, Phio raised an additional $2.2 million through warrant exercises.
Phio Pharmaceuticals (NASDAQ: PHIO) has secured approximately $2.5 million in gross proceeds through the exercise of outstanding warrants. The agreement involves the exercise of warrants to purchase 928,596 shares of common stock, with 100,000 shares at $2.00 per share and 828,596 shares at a reduced price of $2.485 per share.
In exchange for immediate cash exercise, holders will receive new unregistered warrants for up to 1,857,192 shares at $2.485 per share. These new warrants include two tranches: one with a 24-month term for 1,538,596 shares and another with a 5-year term for 318,596 shares. The offering, managed by H.C. Wainwright & Co., is expected to close around July 28, 2025.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced pathology results for four out of five patients in the fourth cohort of its Phase 1b clinical trial for PH-762. The trial evaluates the intratumoral use of PH-762 in various skin cancers. Key results include a complete pathologic response in one cutaneous squamous cell carcinoma (cSCC) patient and a partial response in a Stage 4 metastatic Merkel cell patient.
Across all four cohorts, 15 patients have been treated with no dose-limiting toxicities or clinically relevant adverse effects. Among 13 cSCC patients, five achieved complete response, one near-complete response, one partial response, and six non-responses. The company is now enrolling what is expected to be the final cohort in the Phase 1b study.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
